美国和欧洲临床试验患者幽门螺杆菌分离株的抗菌药物耐药率
在美国和欧洲开展的pHalcon-HP研究采集907例幽门螺杆菌感染成人胃黏膜活检,用琼脂稀释法测定克拉霉素、阿莫西林和甲硝唑的最低抑菌浓度并计算耐药率。总体克拉霉素耐药率为22.2%、阿莫西林为1.2%、甲硝唑为69.2%,美国与欧洲相似;除英国(0/8株)外所有亚区克拉霉素耐药率均≥15%。作者认为该结果反对继续经验性使用含克拉霉素的质子泵抑制剂三联方案。
要点
- 907例分离株中克拉霉素耐药率22.2%,甲硝唑耐药率69.2%,阿莫西林耐药率1.2%。
- 美国与欧洲耐药率相似,甲硝唑耐药最常见(50%-79%),阿莫西林耐药最少(≤5%)。
- 除英国(0/8株)外,所有亚区克拉霉素耐药率均≥15%。
核心结论
- 作者认为观察到的耐药率反对按治疗指南继续经验性使用含克拉霉素的质子泵抑制剂三联方案,并强调美国和欧洲需要抗生素耐药监测和幽门螺杆菌感染的新治疗策略。
研究设计与样本
- pHalcon-HP研究在美国和欧洲开展,于筛查期采集成人幽门螺杆菌感染参与者的胃黏膜活检。
- 用琼脂稀释法测定克拉霉素、阿莫西林和甲硝唑的最低抑菌浓度,折点分别为≥1 μg/mL、>0.125 μg/mL和>8 μg/mL。
- 耐药率按美国、欧洲、美国亚区和参与欧洲国家分别计算,共基于907例参与者的分离株。
主要发现
- 总体22.2%对克拉霉素耐药,1.2%对阿莫西林耐药,69.2%对甲硝唑耐药。
- 美国和欧洲耐药率相似,甲硝唑耐药最常见(50%-79%),阿莫西林耐药最少(≤5%)。
- 所有亚区中≥15%的分离株对克拉霉素耐药,英国除外(0/8株)。
- 克拉霉素耐药分离株中75%同时耐甲硝唑。
- 美国有2株分离株同时对克拉霉素和阿莫西林耐药,其中1株还耐甲硝唑。
关键数值与推荐
- 指南建议在克拉霉素耐药率≥15%的地区或既往使用过大环内酯类药物的患者中,不使用含克拉霉素的质子泵抑制剂三联方案。
- 耐药折点:克拉霉素≥1 μg/mL,阿莫西林>0.125 μg/mL,甲硝唑>8 μg/mL。
临床怎么用
- 作者认为该研究观察到的耐药率反对按治疗指南继续经验性使用含克拉霉素的质子泵抑制剂三联方案。
- 作者强调美国和欧洲需要抗生素耐药监测和幽门螺杆菌感染的新治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Guidelines recommend that proton pump inhibitor-based triple regimens with clarithromycin not be used for Helicobacter pylori infection in areas where clarithromycin resistance is ≥15%, or in patients with prior macrolide use. Up-to-date information on local resistance patterns is limited, especially in the US. Here, we report resistance rates to antibiotics commonly used to treat H. pylori from a large study conducted in the US and Europe (pHalcon-HP). METHODS: Gastric mucosal biopsies were collected from adult participants with H. pylori infection during screening. Minimum inhibitory concentrations were determined via agar dilution for clarithromycin, amoxicillin, and metronidazole, with breakpoints ≥1 μg/mL, >0.125 μg/mL, and >8 μg/mL, respectively. Resistance rates were obtained for the US and Europe, and also for US subregions and participating European countries. RESULTS: Resistance rates were established in isolates from 907 participants. Overall, 22.2% were resistant to clarithromycin, 1.2% to amoxicillin, and 69.2% to metronidazole. Resistance in the US and Europe was similar; metronidazole resistance was the most prevalent (50%-79%) and amoxicillin the least (≤5%). In all subregions, ≥15% of isolates were resistant to clarithromycin, except the UK (0/8 isolates). Among clarithromycin-resistant isolates, 75% were also metronidazole-resistant. Two US isolates were resistant to clarithromycin and amoxicillin; one of these was also metronidazole-resistant. DISCUSSION: The resistance rates observed in this study argue against the continued empiric use of proton pump inhibitor-based triple therapy containing clarithromycin, per treatment guidelines, and highlight the need for antibiotic resistance surveillance and novel treatment strategies for H. pylori infection in the US and Europe.
引用
- Mégraud F, Graham DY, Howden CW, et al. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2022. PMID: 36191284. doi:10.14309/ajg.0000000000002045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。